ArticleJournal of human immunity2026
Clinical experience with emapalumab treatment in a group of children with primary hemophagocytic lymphohistiocytosis.
Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care.Pediatric investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hemophagocytic lymphohistiocytosis (pHLH) is a group of genetically determined disorders characterized by severe and fulminant systemic inflammation, cytopenia, and multiple organ involvement. A dexamethasone-and-etoposide-based HLH-2004 protocol is widely used to treat pHLH, yet often fails to produce the disease control required for the next treatment step: hematopoietic stem cell transplantation (HSCT). We report on the use of the interferon gamma inhibitor emapalumab in seven children aged 6-39 months with pHLH. Three patients received emapalumab at an average starting dose of 1.7 mg/kg and had no active HLH by median day 28. Four patients received emapalumab at an average starting dose of 7.2 mg/kg and had no active HLH by median day 14 (P = 0,0015). We suggest that the higher starting dose of emapalumab, as well as its combination with Janus kinase inhibitors, might increase the remission rate in pHLH and the success of subsequent HSCT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.